Cardiol Therapeutics adds OSC-requested disclosure to US$150 million shelf prospectus filing

• Cardiol filed a preliminary short form base shelf prospectus following an Ontario Securities Commission staff review.
• The filing adds expanded R&D program timelines and cost disclosure, G&A expense breakdowns, and updated use-of-proceeds reporting for an October 2024 financing.
• Management reported no restatement or amendment to previously filed financial statements, expenses, cash flows, or cash position.
• Additional material contracts will be filed alongside the prospectus, including supplier and development agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001279569-26-000875), on September 10, 2026, and is solely responsible for the information contained therein.